BiotechTube

Famciclovir + Placebo

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Genital Herpes

Conditions

Genital Herpes

Trial Timeline

Jun 1, 2007 → Mar 1, 2009

NCT ID
NCT00477334

About Famciclovir + Placebo

Famciclovir + Placebo is a approved stage product being developed by Novartis for Genital Herpes. The current trial status is completed. This product is registered under clinical trial identifier NCT00477334. Target conditions include Genital Herpes.

What happened to similar drugs?

9 of 20 similar drugs in Genital Herpes were approved

Approved (9) Terminated (0) Active (11)
✅Risankizumab + Placebo for RisankizumabAbbVieApproved
✅FamciclovirNovartisApproved
✅FamciclovirNovartisApproved
✅turoctocog alfaNovo NordiskApproved
✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved
✅activated recombinant human factor VIINovo NordiskApproved
✅activated recombinant human factor VII + activated recombinant human factor VII + factor VIIINovo NordiskApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00477334ApprovedCompleted

Competing Products

20 competing products in Genital Herpes

See all competitors
ProductCompanyStageHype Score
mRNA-1608ModernaPhase 2
0
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
Fulvestrant + AbemaciclibEli LillyPhase 2
39
EDIT-101Editas MedicinePhase 1/2
18
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
40
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
ASP2151 + PlaceboAstellas PharmaPhase 1
29
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Topical NO + PlaceboKyowa KirinPhase 2
35
KW-3357Kyowa KirinPhase 1
29
Ixekizumab + PlaceboEli LillyPhase 3
40
Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
40
DaratumumabJohnson & JohnsonPhase 2
27